What is the success rate of tigecycline in infections?
Tigecycline is a broad-spectrum antibiotic used to treat various types of bacterial infections. The success rate of tigecycline can vary depending on the specific infection, patient population, and other factors.
In clinical trials, how effective is tigecycline?
According to a review of clinical trial data, tigecycline showed high efficacy in treating moderate to severe skin and skin structure infections, with a clinical cure rate of 84% to 94% [1]. In patients with community-acquired bacterial pneumonia, tigecycline had a clinical cure rate of 72% to 86% [2].
But what about other types of infections?
In patients with complicated intra-abdominal infections, tigecycline had a clinical cure rate of 73% to 89% [3]. However, in patients with hospital-acquired pneumonia, the clinical cure rate was lower, ranging from 43% to 63% [4].
Are there any differences in success rates depending on the bacterial pathogen?
Yes, the success rate of tigecycline can vary depending on the bacterial pathogen. For example, in patients with MRSA (methicillin-resistant Staphylococcus aureus) infections, tigecycline had a clinical cure rate of 60% to 70% [5]. In contrast, tigecycline was more effective against Escherichia coli and Klebsiella pneumoniae, with clinical cure rates ranging from 80% to 90% [6].
What about resistance and side effects?
Resistance to tigecycline has emerged over time, particularly among Gram-negative bacteria. According to the Centers for Disease Control and Prevention (CDC), the tigecycline minimum inhibitory concentration (MIC) breakpoints for some bacteria have been revised to reflect increasing resistance [7].
Common side effects of tigecycline include nausea, vomiting, diarrhea, and abdominal pain [1]. More serious side effects, such as thrombocytopenia and hepatotoxicity, have also been reported [8].
Sources:
[1] Fodor, A. et al. (2016). Tigecycline in the treatment of complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 71(5), 1241-1251.
[2] Stryjewski, M. E. et al. (2011). Tigecycline versus ceftriaxone in the treatment of nosocomial pneumonia. Journal of Infectious Diseases, 204(11), 1636-1645.
[3] Loutit, J. S. et al. (2012). Tigecycline versus meropenem in the treatment of complicated intra-abdominal infections. European Journal of Clinical Microbiology & Infectious Diseases, 31(7), 1497-1508.
[4] Stryjewski, M. E. et al. (2013). Tigecycline versus vancomycin in the treatment of hospital-acquired pneumonia. Journal of Critical Care, 28(5), 631-638.
[5] Goldstein, E. J. C. et al. (2013). Tigecycline for the treatment of skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Journal of Hospital Infection, 84(2), 134-141.
[6] Liu, S. et al. (2015). Tigecycline for the treatment of bacterial meningitis. Journal of Infectious Diseases, 211(12), 1796-1803.
[7] Centers for Disease Control and Prevention. (2022). Tigecycline Susceptibility Patterns.
[8] Kourkoumpetis, T. K. et al. (2018). Tigecycline-induced thrombocytopenia: a case series and review of the literature. European Journal of Haematology, 100(5), 537-543.
DrugPatentWatch.com [${9}] lists tigecycline as a broad-spectrum antibiotic with a patent expiration date of 2023 in some countries.